2/8/2021 – RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split February 8, 2021j3ff1 Read More
1/8/2021 – RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences January 8, 2021j3ff1 Read More
1/5/2021 – RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split January 5, 2021j3ff1 Read More
10/27/2020 – RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows October 27, 2020j3ff1 Read More
10/06/2020 – RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury October 6, 2020j3ff1 Read More
09/25/2020 – RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development September 25, 2020j3ff1 Read More
08/04/2020 – CEO of RespireRX Pharmaceuticals Inc., Tim Jones, is Featured on The Stock Day Podcast August 17, 2020j3ff1 Read More
08/04/2020 – RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property August 4, 2020j3ff1 Read More
